INIS
administration
6%
AIDS
11%
antibiotics
12%
aspirin
9%
children
9%
concentration
12%
control
8%
coronaries
9%
coronaviruses
9%
corticosteroids
9%
cost effectiveness analysis
9%
covid-19
10%
cytochromes
9%
diseases
13%
doses
20%
drugs
20%
failures
8%
genes
19%
genetic variability
9%
genetics
9%
genotype
15%
hiv
20%
hospitals
33%
indonesia
14%
interactions
10%
leprosy
9%
leukemia
9%
lungs
19%
magnesium
9%
maintenance
9%
malaria
19%
management
9%
methyl transferases
9%
mice
9%
mutations
10%
myeloid leukemia
13%
pain
9%
patients
100%
pharmacology
9%
pharmacotherapy
9%
phenotype
12%
plasma
13%
plasmodium
19%
reviews
9%
risks
9%
safety
13%
safety analysis
9%
surveys
9%
therapy
26%
tuberculosis
29%
Keyphrases
Acute Coronary Syndrome
9%
Adverse Effects
15%
AIDS/HIV
14%
Angiotensin-converting Enzyme 2 Receptor
9%
Antiretroviral
11%
Antiviral Treatment
9%
Aspirin
9%
Chloroquine and Hydroxychloroquine
11%
Chronic Myeloid Leukemia
17%
Clinical Pharmacology
9%
Clopidogrel
9%
Comorbid
9%
Corticosteroids
9%
Cost-effectiveness Analysis
9%
COVID-19
20%
Cytochrome P450 2D6 (CYP2D6)
9%
Daily Dose
10%
Database Study
19%
Dual Antiplatelet Therapy
9%
Efavirenz
16%
Falciparum Malaria
19%
Genotype
14%
Hematotoxicity
9%
HIV Viral Load
9%
Imatinib
11%
Indonesia
14%
Indonesian
30%
Leprosy Patients
9%
Leukemia Patients
18%
Lung Tuberculosis
9%
Major Molecular Response
15%
Molecular Docking
9%
Narrative Review
9%
Pain Management
9%
Pain Pharmacology
9%
Plasma Concentration
11%
Post-cesarean Section
9%
Primaquine
12%
Prospective Survey
9%
Quinine
9%
Radical Cure
10%
Real-time Database
9%
Retrospective Cohort Study
12%
Rifampicin
19%
Safety Analysis
9%
Therapeutic Effectiveness
9%
Therapeutic Efficacy
9%
Tuberculosis
14%
Tuberculosis Infection
9%
Tuberculosis Treatment
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
9%
Acute Coronary Syndrome
9%
Adverse Event
6%
Angiotensin Converting Enzyme 2
9%
Antiplatelet
9%
Antivirus Agent
9%
Cardiovascular Disease
6%
Chloroquine
18%
Chronic Myeloid Leukemia
14%
Clinical Pharmacology
9%
Clopidogrel
9%
Cohort Study
14%
Combination Therapy
11%
Coronavirinae
9%
Cross-Sectional Study
6%
CYP2D6
9%
Diabetes Mellitus
9%
Diseases
19%
Efavirenz
16%
HIV
20%
Hydroxychloroquine
14%
Imatinib
19%
Infection
5%
Lopinavir Plus Ritonavir
5%
Lung Tuberculosis
9%
Peptidase
5%
Piperine
9%
Placebo
9%
Plasmodium Vivax Malaria
19%
Primaquine
12%
Receptor
9%
Recurrence Risk
9%
Recurrent Disease
9%
Rifampicin
19%
SARS Coronavirus
5%
Side Effect
12%
Tafenoquine
9%
Thiopurine Methyltransferase
7%
Tuberculosis
9%